Loading news...
Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Cinctive Capital Management LP trimmed its position in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 49.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 310,313 shares of the company's stock after selling 305,431 shares during the period. Cinctive Capital Management LP owned 0.20% of Adaptive
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 141,583 shares of the firm's stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $13.29, for a total value of $1,881,638.07. Following the transaction, the chief operating officer owned 516,610 shares in the company, valued
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) insider Harlan Robins sold 470,266 shares of Adaptive Biotechnologies stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total value of $6,193,403.22. Following the completion of the transaction, the insider owned 1,522,058 shares in the company,
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) CEO Chad Robins sold 470,167 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total value of $6,192,099.39. Following the completion of the transaction, the chief executive officer directly owned 2,301,113 shares in
Allianz Asset Management GmbH boosted its position in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 305.8% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 321,774 shares of the company's stock after acquiring an additional 242,474 shares during the quarter. Allianz Asset
Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) CEO Chad Robins sold 124,998 shares of the business's stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $18.44, for a total value of $2,304,963.12. Following the completion of the sale, the chief executive officer directly owned 2,459,245 shares
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.23 per share a year ago.
SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2025.
SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.
SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
SG Americas Securities LLC increased its position in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 82.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 68,113 shares of the company's stock after buying an additional 30,785 shares during
Adaptive Biotechnologies Corporation (ADPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025. Total revenue for the fourth quarter and full year 2025 was approximately $72 million and $277 million, representing an increase of 51% and 55%, respectively, over the corresponding periods in 2024.
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) insider Harlan Robins sold 10,000 shares of the business's stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.44, for a total transaction of $164,400.00. Following the completion of the transaction, the insider directly owned 1,222,312 shares of the
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) CEO Chad Robins sold 124,998 shares of the business's stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $15.59, for a total transaction of $1,948,718.82. Following the completion of the transaction, the chief executive officer owned 2,584,243 shares of
Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive Biotechnologies, has raised fresh cash as part of an initial closing of a Series A investment round.
VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 54,100 shares of the company's stock, valued at approximately $809,000. A number of other hedge funds have